These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20939443)

  • 1. Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance.
    Prescrire Int; 2010 Aug; 19(108):158. PubMed ID: 20939443
    [No Abstract]   [Full Text] [Related]  

  • 2. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
    Croom KF; Siddiqui MA
    Drugs; 2009 Jul; 69(11):1513-32. PubMed ID: 19634927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Few options available for arthritis pain relief. FDA declines to approve Merck's Arcoxia.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(10):1020-2. PubMed ID: 17494894
    [No Abstract]   [Full Text] [Related]  

  • 4. A case report on toxic epidermal necrolysis with etoricoxib.
    Kameshwari JS; Devde R
    Indian J Pharmacol; 2015; 47(2):221-3. PubMed ID: 25878388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-selective NSAIDs and coxibs: what are myths, what are facts?].
    MMW Fortschr Med; 2013 Jun; 155(12):56-7. PubMed ID: 23923320
    [No Abstract]   [Full Text] [Related]  

  • 8. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D
    MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical pharmacology of etoricoxib.
    Capone ML; Tacconelli S; Patrignani P
    Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):269-82. PubMed ID: 16922642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging from the shadow of Vioxx.
    Lindsley CW
    Curr Top Med Chem; 2007; 7(7):739. PubMed ID: 17450647
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs.
    Di Leo E; Aloia AM; Nettis E; Cardinale F; Foti C; Distaso M; Ferrannini A; Vacca A
    Int J Immunopathol Pharmacol; 2009; 22(4):1131-4. PubMed ID: 20074479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
    Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
    [No Abstract]   [Full Text] [Related]  

  • 15. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk for complications after colorectal surgery with selective cyclo-oxygenase 2 inhibitor etoricoxib.
    Zittel TT; Razavi D; Papp A; Lundberg K
    Dis Colon Rectum; 2013 Jun; 56(6):761-7. PubMed ID: 23652751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed drug eruption and generalised erythema following etoricoxib.
    Augustine M; Sharma P; Stephen J; Jayaseelan E
    Indian J Dermatol Venereol Leprol; 2006; 72(4):307-9. PubMed ID: 16880582
    [No Abstract]   [Full Text] [Related]  

  • 18. Pain management after elective hallux valgus surgery: a prospective randomized double-blind study comparing etoricoxib and tramadol.
    Brattwall M; Turan I; Jakobsson J
    Anesth Analg; 2010 Aug; 111(2):544-9. PubMed ID: 20584877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing.
    Andrade P; Gonçalo M
    Contact Dermatitis; 2011 Feb; 64(2):118-20. PubMed ID: 21210830
    [No Abstract]   [Full Text] [Related]  

  • 20. Etoricoxib-induced toxic epidermal necrolysis.
    Moutran R; Maatouk I; Hélou J
    Int J Dermatol; 2014 Apr; 53(4):e275-7. PubMed ID: 23879726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.